complicated type 1 diabetes mellitus. 1 Currently, the portal vein is the preferred surgical site for islet transplantation 2 ; however, direct contact of islets with portal blood triggers early inflammatory reactions, termed instant blood-mediated inflammatory reactions (IBMIR), and consequently leads to 60%-70% loss of implanted islets within the first few hours or days post-transplantation. 3, 4 To overcome this limitation, alternative extra-hepatic transplantation sites have been exploited in rodents and nonhuman primates. These include the kidney subcapsule, omentum, gastrointestinal wall, bone marrow, subcutaneous tissue, and anterior chamber of the eye. 5, 6 Of these, subcutaneous spaces offer the best surgical advantages in terms of ease of accessibility for implantation and removal of grafts and routine monitoring by biopsy with minimal complications. 5 However, the clinical application of this site is hampered by the low oxygen tension due to poor perfusion, which consequently results in the need to transplant comparatively high amounts of viable islets in order to control diabetes. 7, 8 In this regard, optimization of the subcutaneous tissue transplant site through innovative modalities, such as artificial devices promoting neovascularization, is necessary in order for this to become an appropriate route for islet transplantation.
Several such techniques have been reported in experimental mouse models. For instance, graft vascularization and survival were enhanced to varying degrees by the addition of an extracellular matrix, stem cell co-transplantation, the use of an oxygen-supplying system, or hypoxia-resistant gene transfer. [8] [9] [10] [11] [12] [13] However, to translate these modalities to the clinic several concerns must first be addressed including biosafety, the need to increase efficacy comparable to highly vascularized organs such as the kidney capsule, and simplification of difficult manipulation procedures.
Poly(lactic-co-glycolic) acid (PLGA) is an FDA-approved copolymer that exhibits excellent biodegradability, biocompatibility, and biosafety. 14 Currently, it is being used in biomedical devices including grafts, implants, and prosthetic devices. 15 Therefore, in this study, we attempted to construct a PLGA-based bio-artificial device as a modality for subcutaneous islet transplantation. Hypoxiapreconditioned mesenchymal stem cells (hypo-MSC) were applied to this device to promote vascularization in vivo. Recently, mesenchymal stem cells have been widely studied for tissue engineering of bone, muscle, cartilage, tendon, and other tissues in preclinical models. 16 These cells have shown considerable promise for use in rebuilding damaged or diseased mesenchymal tissue. 17 Moreover, culturing mesenchymal stem cells under low oxygen tension has shown great therapeutic potential in mesenchymal stem cell-based regenerative therapy. 18 The culture of mesenchymal stem cells in hypoxia conditions greatly enhances in vitro cell survival and secretion of growth factors related to angiogenesis. 19, 20 In addition, the transplantation of hypoxia-preconditioned bone marrow mesenchymal stem cells has been shown to enhance angiogenesis and neurogenesis after cerebral ischemia. 21, 22 Thus, culture of MSCs in low oxygen in vitro prior to transplantation should increase the vascularization potential of the subcutaneous tissue, thereby increase the efficacy of this modality as an extra-hepatic transplantation site.
In this study, we used adult porcine islets because they have recently been considered ideal for xenogeneic islet transplanta- 
| MATERIAL S AND ME THODS

| Animals
Immunodeficient non-obese diabetic/severe combined immunodeficient mice (NOD/SCID, Jackson Laboratories, Bar Harbor, ME, USA) between 8-12 weeks of age were housed in Specific Pathogen-Free (SPF) animal facilities of the Seoul National University (SNU) were used for these experiments. All experimental procedures were conducted in accordance with the guidelines of the Institutional Animal
Care and Use Committee of the SNU. Porcine islets were isolated from SNU miniature pigs or local slaughterhouse adult pigs. SNU miniature pigs were bred and maintained in a barrier-sustained SPF facility. 23 
| Isolation and culture of mice bone-marrow (BM)-derived MSCs
Isolation and culture of MSCs and GFP-MSCs were performed as previously described. 24 Briefly, femurs and tibias removed from murine long bones were ground using a mortar with Phosphate-Buffered 
| Flow cytometric analysis
| Islet isolation and culture conditions
Whole islet isolation and enrichment procedures were conducted using the modified Ricordi method as previously described. 25 Table S1 .
| Preparation of PLGA scaffolds
Poly (lactide-co-glycolide) (PLGA) scaffolds were prepared with PLGA powder (Mw = 97 000, 8.5 wt%; Boehringer Ingelheim, Ingelheim, Germany) and NaCl (diameter = 300-500 μm, average 92% wt). A sintering method was used for preparing these scaffolds, as described in our previous reports. 28 PLGA homogeneously mixed with salt was placed in a disk mold. This mixture was pressed with a hydraulic press at 150 MPa for 3 minutes at room temperature. Generated solid disks were then thermally treated at 210°C for 30 minutes. The NaCl particles contained in the scaffolds were leached by distilled water. Sheet-typed PLGA devices were constructed into a transplantable size (length × width × height = 8 × 5 × 1.5 mm). Devices were pierced with a needle to make a hole and filled with a Teflon stopper before implantation. A photograph of the PLGA devices is shown in Figure 4A . Normal saline was also directly injected into the cell-free PLGA bed of the mice as a negative control. Vasculature formation was monitored at 3-6 weeks after PLGAs were implanted. Figure 4A illustrates the entire procedure of islet transplantation inside of were removed approximately 100 days post-transplant of islets to evaluate the graft's function or on the days in which mice were sacrificed. Graft rejection was defined as a rise in blood glucose to >300 mg/dL for at least two consecutive measurements. The mean post-transplantation blood glucose level was calculated as the average concentration of blood glucose from 2-3 days to 100 days after islet transplantation or to the day in which mice were sacrificed. A marginal islet mass was defined as a specified dose of IEQs with which approximately 50% of the diabetic mice return to normoglycemia after islet transplantation.
| PLGA/MSC composite preparation, vascularization and islet transplantation
| Induction of diabetes mellitus
Diabetes was induced in mice by injecting streptozotocin (125 mg/kg/day; Sigma) by the intraperitoneal (IP) route for 2 consecutive days. Non-fasting blood glucose levels were monitored with a glucometer (LIFESCAN Inc., Milpitas, CA, USA). Mice with non-fasting blood glucose levels higher than 400 mg/dL for two consecutive days were used as recipients for subsequent islet transplantation.
| Ex vivo measurement of hemoglobin content
The colorimetric cyanmethemoglobin method was used to measure the hemoglobin content to determine the amounts of neovasculature formed in the grafts, as previously described. Grafts were visualized with a digital camera (Nikon Infinity, Melville, NY, USA) attached to a light microscope (Nikon ECLIPSE TS 100).
| Statistical analyses
All statistical data analyses were performed with GRAPHPAD PRISM5 (GraphPad Software, San Diego, CA, USA) with Mann-
Whittney test with two-tailed P-values or with Kaplan-Meier
Survival analysis. A P value <0.05 was considered significant: *P < 0.05; **P < 0.01; ***P < 0.001.
| RE SULTS
| Characterization of hypo-MSCs
Hypo-MSCs were used to promote vasculature formation in a subcutaneously-transplanted PLGA device. Following passage of MSCs 5-10 times over 7 days under the conditions of 3% O 2 and 5% CO 2, hypo-MSCs were generated. In Figure 1 , hypo-MSCs and normo-MSCs were compared phenotypically. Hypo-MSCs and normo-MSCs express the MSC-specific markers CD29, CD44, and CD105, and are negative for CD45 and CD14. Additionally, chemokine receptors including CCR4, CCR7, CXCR3, and CXCR4 were more markedly increased in hypo-MSCs compared to normo-MSCs. CD62L was not expressed on either type of MSCs. The endothelial marker, CD31, was not expressed on hypo-MSCs nor normo-MSCs, while angiogenesis-related markers, such as VEGFR2, vWF, VEGF, and FGF, were upregulated in hypo-MSCs to various degrees.
| Vasculature formation in bio-artificial PLGA beds by hypo-MSCs
The potential of hypo-MSCs to promote neovascularization was examined using subcutaneously-transplanted bio-artificial PLGA devices. 
| Time-lapse monitoring of vasculogenesis in hPLGAs: Determination of the optimum time for islet transplantation
To determine the best time for subsequent islet transplantation, serial time-lapse monitoring of vasculogenesis was performed. As shown in Figure 3A , the total hemoglobin content of the implanted PLGA devices coated with hypo-MSC (hPLGA) was maximized at 4 weeks; however, the hemoglobin content per weight of the device continued to increase until 6 weeks after implantation ( Figure 3C ) due to the gradual loss of PLGA scaffolds ( Figure 3B ) probably through hydrolytic degradation. Moreover, it was technically difficult to transplant islets 6 weeks after PLGA implantation due to the low mechanical strength of the PLGA scaffolds. As shown in Figure 3D , high amounts of vasculature were apparent on the interior and exterior surfaces of the devices. Taking into consideration the maximum vascularization and optimum mechanical strength of the PLGA beds, we determined that the optimal time for subsequent islet transplantation should be between 4-5 weeks after hPLGA implantation. were then delivered into the hole of the pre-vascularized devices.
| Superior control of diabetes by porcine islets in the prevascularized PLGA-based bed
Mice were divided into three experimental groups: the hPLGA group (n = 6), consisting of the mice transplanted with porcine islets into the hypo-MSC-loaded PLGA devices, the nPLGA group (n = 6), consisting of the mice transplanted with porcine islets into the normo-MSC-loaded PLGA devices, and the cell-free PLGA group (n = 6), consisting of the mice transplanted with porcine islets into the cell-free PLGA devices. Of note, as shown in Figure 4C ,D, all of the diabetic mice in the hPLGA group regained normoglycemia (6 of 6); however, only 67% of mice in the nPLGA group (4 of 6) and 17% of mice in the cell-free PLGA group (1 of 6) recovered from diabetes. Hyperglycemia recurred when grafts were removed approximately 100 days after islet transplantation, suggesting that implanted islets were entirely responsible for the normoglycemia (arrow in Figure 4C ).
In addition, compact connective tissue and abundant vasculature covered the hPLGA bed at 100 days after islet transplantation ( Figure 4B ).
| Reduction in marginal islet mass to a level similar to that required for the transplantation of islets into the highly vascularized kidney subcapsule
Marginal islet mass is defined as sub-curable dose of islet mass curing 50% of diabetic mice. Determination of the marginal islet F I G U R E 3 Analysis of vasculogenesis and degradation of PLGA devices over time shows 4-5 wk after hPLGA implantation is optimal for islet transplantation. PLGA devices loaded with hypo-MSCs were implanted subcutaneously in mice, and the total hemoglobin content (A), weight of the PLGA grafts (B), hemoglobin content per weight of the PLGA grafts (C) were assessed at the designated time after transplantation. D, Photograph of vasculogenesis on the interior and exterior surface of the PLGA grafts. The P values are defined as follows: *P < 0.05; **P < 0.01; ***P < 0.001; ns P > 0.05 mass is necessary to assess the efficacy of the device. Various doses of islet equivalents (IEQs) were infused into the hPLGA implanted in the subcutaneous sites of the STZ-induced diabetic mice. As shown in Figure 5 , a marginal islet mass for the hPLGAs in the subcutaneous site was approximately 2000 IEQs, which is comparable to that required for the transplantation of naked porcine islets into the kidney subcapsule, as reported in our previous study.
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| D ISCUSS I ON
In this study, we demonstrate the high efficacy of hypoxiapreconditioned MSCs for the promotion of vasculogenesis in bio-artificial PLGA devices implanted subcutaneously into mice.
Prevascularized devices allowed islets to be engrafted efficiently into a poorly vascularized site, resulting in the amelioration of diabetes and increased glycemic control in the pig to mouse subcutaneous F I G U R E 4 Superior diabetic control in mice following the transplantation of porcine islets into PLGA beds prevascularized with hypoMSCs. A, Schematic representation of the entire procedure for subcutaneous islet transplantation using prevascularized PLGA beds. Collagencoated sheet-type PLGA devices are loaded with normo-MSCs or hypo-MSCs and cell-loaded devices are subcutaneously implanted into the mouse lateral abdominal region. Cell-free PLGA devices are implanted into the same subcutaneous tissue as a control. All devices have two holes sealed with a Teflon stopper. Two wk after implantation, additional normo-MSCs, hypo-MSCs, and normal saline are injected into the implantation area of the individual PLGA devices to enhance vasculogenesis. Two weeks later, porcine islets (5000 IEQs) are transplanted into the hole of the PLGA bed of STZ-induced diabetes mice after removal of the Teflon stopper. B-D, Superior diabetic control following porcine islet transplantation into hPLGA beds of STZ-induced diabetic mice. Mice were divided into three experimental groups: the hPLGA group (n = 6), consisting of mice with prevascularized, hypo-MSC-loaded PLGA devices; the nPLGA group (n = 6), consisting of mice with prevascularized, normo-MSC-loaded PLGA devices; and the cell-free PLGA group (n = 6), consisting of mice with cell-free PLGA devices. Porcine islets (5000 IEQs) were transplanted into the hole of individual PLGA devices after the removal of the Teflon stopper. Non-fasting blood glucose levels of the mice were monitored twice within the 100 d following transplantation or until the mice were sacrificed. Grafts were removed approximately 100 d after transplantation to evaluate function, as indicated by the arrow (C). The percent recovery from diabetes was calculated using Kaplan-Meier Survival analysis (D). All diabetic mice transplanted with hPLGA supported complete glycemic control after porcine islet transplantation. Photographs of the surface of the grafts were obtained 100 d after islet transplantation (B). The P values are defined as follows: *P < 0.05; ***P < 0.001; ns P > 0.05 islet transplantation model. Moreover, there was a significant reduction in the marginal islet mass required to cure 50% of diabetic mice, which was comparable to that for the kidney subcapsular space, a highly vascularized site.
Clinical application of the subcutaneous site for islet transplan- Transplanting islets into a subcutaneous site prevascularized with basic fibroblast growth factor-impregnated gelatin microspheres or biocompatible devices consisting of a cylindrical stainless steel mesh cured diabetes in mice. 7, 10 However, designing PLGA-based bio-artificial devices has many safety and application advantages over these approaches including the ease with which this product is shaped into various forms and the ability to modulate the porosity.
Preliminary experiments with globular-shaped PLGA revealed a lack of vasculogenesis in areas inside the device where cells could not form contact (Data not shown). Therefore, in this study, we designed sheet-type PLGA devices with 92% porosity and transplanted them underneath the skin of the mice. As shown in Figure 2 , small amounts of microvasculature were generated on the interior and exterior surfaces of implanted PLGA devices; however, the levels
were not sufficient to support maximum islet engraftment in order to reverse diabetes. Therefore, to improve vasculature formation, hypoxia-preconditioned mesenchymal stem cells were applied to the PLGA device. vivo. Notably, high amounts of vasculature were generated inside the PLGA devices, which would be critical for maximum engraftment of transplanted islets, when islets were infused inside the devices.
Therefore, we designed the device to have holes that penetrate the center longitudinally in order to transplant islets into the inside of the devices. In addition, the optimum time for islet transplantation was determined based on maximum vasculature formation and sufficient mechanical strength for islet transplantation (Figure 3 ).
The overall strategy for subcutaneous islet transplantation using prevascularized-PLGA devices is explained in Figure 4A . Several factors were considered when designing this strategy including safety, efficacy, simplicity, and ease of application. Regarding safety, this strategy employs FDA-approved PLGA, which may have high clinical relevance in therapeutic subcutaneous islet transplantation. With regarding to efficacy, a common drawback of many previously reported modalities developed for subcutaneous islet transplantation is that there is no quantitative validation to evaluate their efficacy in terms of diabetes recovery. For this reason, we compared the diabetes reversal rate in the pig to mouse islet transplantation model where 5000 IEQ of porcine islets were infused into prevascularized devices previously implanted into diabetic mice. We observed superior glycemic control in mice transplanted with porcine islets in the hypo-MSC F I G U R E 5 Determination of the marginal islet mass required for complete control of diabetes in mice. Various masses of porcine islets (IEQs) (5000 IEQs (n = 6), 3000 IEQs (n = 5), 2000 IEQs (n = 5), and islet-free PLGA (n = 3)) were transplanted into the subcutaneously imbedded, prevascularized hPLGA beds of STZ-induced diabetic mice. The mean post-transplantation blood glucose level was calculated as the average concentration of blood glucose from 2-3 to 100 d after islet transplantation, or to the day on which the mice were sacrificed. Less than 200 mg/mL of mean post-transplantation blood glucose level (dotted line) was considered to be normoglycemic conditions. The marginal islet mass, defined as a specified dose of IEQs at which approximately 50% of the diabetic mice return to normoglycemic conditions after transplantation of islets, was monitored as a means of determining device efficacy preconditioned device compared to that of the normo-MSC preconditioned or non-preconditioned devices. We also determined the marginal islet mass for the subcutaneous site and compared it with that of the kidney subcapsular space, a highly vascularized site. Our previous study revealed a marginal islet mass of approximately 2000 IEQs for transplantation into the kidney subcapsule of mice. 8 In this study, comparable amounts of porcine islets were necessary to cure diabetes in the subcutaneous transplant site with the aid of prevascularized PLGA devices ( Figure 5 ). It is noteworthy that a marginal islet mass of over 20 000 IEQs was required when porcine islets were transplanted into a device-free subcutaneous site. 8 We inferred from our previous study that the liver requires six times more autologous marginal islet mass than the kidney capsule to maintain normal blood glucose levels in mice. 31 Therefore, transplanting islets into the subcutaneous site in the context of prevascularized PLGA devices may reduce the required islet mass to a level lower than that seen when transplanting into the liver, which is a site currently used clinically for allogeneic islet transplantation. Regarding the need for simplicity, further refinements of the methodologies reported here may be helpful for the translation of this device to the clinic. For example, direct injection of islets into the holes in prevascularized-devices might obviate the need for repeated surgical incision of the implanted site. In addition, it will be necessary to clarify whether the additional secondary MSC injection is prerequisite for facilitating islet engraftment in our experimental protocol.
Regarding the application aspect, this device may be a useful mediator for achieving local immune suppression to prevent or minimize graft rejection mediated by local inflammation if combined with a controlled release system of immunosuppressive agents. Studies regarding the possible involvement of supplementary MSCs in generating an immunosuppressive microenvironment in PLGA devices may also be interesting in order to protect grafts from attack by the host immune system. 24 A detailed investigation of this possibility will be carried out in subsequent experiments. In addition, experiments using larger animals, such as monkeys, may be necessary leading up to clinical trials of this device. 
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